Cargando…

Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials

OBJECTIVE: The efficacy of cannabidiol (CBD) with and without concomitant clobazam (CLB) was evaluated in stratified analyses of four large randomized controlled trials, two in Lennox‐Gastaut syndrome, and two in Dravet syndrome. METHODS: Each trial of CBD (Epidiolex(®) in the US; Epidyolex(®) in th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Devinsky, Orrin, Thiele, Elizabeth A, Wright, Stephen, Checketts, Daniel, Morrison, Gilmour, Dunayevich, Eduardo, Knappertz, Volker
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689899/ https://www.ncbi.nlm.nih.gov/pubmed/32592183 http://dx.doi.org/10.1111/ane.13305

Ejemplares similares

Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials
por: Gunning, Boudewijn, et al.
Publicado: (2020)

Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study
por: Thiele, Elizabeth, et al.
Publicado: (2019)

Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial
por: Miller, Ian, et al.
Publicado: (2020)

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
por: Devinsky, Orrin, et al.
Publicado: (2018)

A Phase 2, Double‐Blind, Placebo‐Controlled Trial to Investigate Potential Drug‐Drug Interactions Between Cannabidiol and Clobazam
por: VanLandingham, Kevan E., et al.
Publicado: (2020)

A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects
por: Morrison, Gilmour, et al.
Publicado: (2019)

Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions
por: Anderson, Lyndsey L., et al.
Publicado: (2019)

Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial
por: Thiele, Elizabeth A., et al.
Publicado: (2020)

Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials
por: Madan Cohen, Jennifer, et al.
Publicado: (2021)

Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial
por: Devinsky, Orrin, et al.
Publicado: (2018)

Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6
por: Wu, Joyce Y., et al.
Publicado: (2022)

Clobazam and Its Use in Epilepsy
por: Pernea, Marius, et al.
Publicado: (2016)

Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials
por: Privitera, Michael, et al.
Publicado: (2021)

The clobazam metabolite N-desmethyl clobazam is an α2 preferring benzodiazepine with an improved therapeutic window for antihyperalgesia
por: Ralvenius, William T., et al.
Publicado: (2016)

Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial
por: Watkins, Paul B., et al.
Publicado: (2020)

Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results
por: Szaflarski, Jerzy P., et al.
Publicado: (2018)

Hypothermia associated with clobazam use in adult epilepsy
por: Gauthier, Angela C., et al.
Publicado: (2016)

Effects of clobazam for treatment of refractory status epilepticus
por: Madžar, Dominik, et al.
Publicado: (2016)

A Comprehensive Overview of the Clinical Pharmacokinetics of Clobazam
por: Tolbert, Dwain, et al.
Publicado: (2018)

Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox–Gastaut syndrome
por: Faulkner, Michele A
Publicado: (2015)

Effect of clobazam as add-on antiepileptic drug in patients with epilepsy
por: Joshi, Rupa, et al.
Publicado: (2014)

Systematic review of clobazam use in patients with status epilepticus
por: Mahmoud, Sherif Hanafy, et al.
Publicado: (2018)

Effect of plasmapheresis on serum levels of clobazam, levetiracetam and topiramate
por: Hau Man, To Harmony, et al.
Publicado: (2017)

CLOBAZAM SINGLE OR DIVIDED DOSE AGAINST DIAZEPAM IN ANXIETY NEUROSIS
por: Channabasavanna, S.M., et al.
Publicado: (1986)

A CONTROL CLINICIAL TRIAL OF A NEW ANXIOLYTIC ‘CLOBAZAM’
por: Singh, Gurmeet, et al.
Publicado: (1984)

Clobazam: The phoenix drug (from the very old to the brand new)
por: Guerreiro, Carlos A. M.
Publicado: (2014)

Efficacy and Side Effect Profile of Clobazam in Children with Different Etiologies of Epilepsy from a Single Center
por: Uzunhan, Tugce Aksu, et al.
Publicado: (2020)

Clobazam as an adjunctive therapy in treating seizures associated with Lennox–Gastaut syndrome
por: Leahy, Jennifer T, et al.
Publicado: (2011)

Design Optimization and In Vitro-In Vivo Evaluation of Orally Dissolving Strips of Clobazam
por: Bala, Rajni, et al.
Publicado: (2014)

Rare but life-threatening aspiration pneumonia related to initiation of clobazam therapy
por: Aung, Thandar, et al.
Publicado: (2020)

Macroglossia Associated With Clobazam Administration: A Case Report and Literature Review
por: Zhang, Jeff F., et al.
Publicado: (2022)

Dietary Transitions and Health Outcomes in Four Populations – Systematic Review
por: Pressler, Mariel, et al.
Publicado: (2022)

Evaluation of efficacy and safety of clobazam as an add-on drug in the treatment of generalized tonic-clonic seizure not controlled with valproic acid monotherapy
por: Das, Somenath, et al.
Publicado: (2023)

Phenytoin induced chorea in a pediatric patient: An interaction between phenytoin, phenobarbital and clobazam
por: Barvaliya, Manish, et al.
Publicado: (2011)

Clinical considerations in transitioning patients with epilepsy from clonazepam to clobazam: a case series
por: Sankar, Raman, et al.
Publicado: (2014)

Does orally dissolving formulation of clobazam provide clinical advantage over it's standard formulation
por: Patil, Anant Dhondopant
Publicado: (2016)

Deconstructing tolerance with clobazam: Post hoc analyses from an open-label extension study
por: Gidal, Barry E., et al.
Publicado: (2016)

Use and cost comparison of clobazam to other antiepileptic drugs for treatment of Lennox-Gastaut syndrome
por: François, Clément, et al.
Publicado: (2017)

17.1 A RANDOMIZED CONTROLLED TRIAL OF CANNABIDIOL IN SCHIZOPHRENIA
por: McGuire, Philip, et al.
Publicado: (2018)

A stability indicating HPLC method for the determination of clobazam and its basic degradation product characterization
por: Souri, Effat, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_994c3vmlkqgfgriio6mu7naebr